TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors AUSTIN, TX, and HAMILTON, ON, August 30, 2018 – Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on...
Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more...
Innovative immuno-therapy company welcomes former President and COO of Celgene AUSTIN, Texas & TORONTO–(BUSINESS WIRE)–Triumvira Immunologics, Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to...
Brings 30-years of Experience to Company’s Technology Development and Manufacturing Operations AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack...
Sachs Immuno-Oncology BD&L and Investment Forum and 2018 BIO International Convention AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack...
Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics AUSTIN, Texas & HAMILTON, Ontario – Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack...
